결핵균 치료 시장 : 제품 유형별, 최종사용자별, 지역별 - 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

Mycobacterium Tuberculosis Treatment Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032

US $ 4,995 ￦ 7,055,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,304,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,999,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research의 결핵균 치료 시장 조사 보고서에서는 2024-2032년 시장 동향, 성장 촉진요인·과제, 향후기술 혁신을 상세 분석하고 있습니다. 시장의 현황과 예측에 관한 인사이트를 제공합니다.

세계의 결핵균 치료제 시장은 2024년 21억 3,000만 달러에서 2032년에는 24억 달러로, CAGR 1.2%를 달성할 것으로 예측됩니다.

주요 인사이트

• 추정 시장 규모(2024년) : 21억 3,000만 달러
• 예측 시장 규모(2032년) : 24억 달러
• 세계 시장 성장률(CAGR 2024-2032년) : 1.2%

결핵균 치료 시장 - 리포트 범위 :

결핵균은 결핵을 유발하는 박테리아로 주로 폐를 침범하지만 다른 장기에도 침입할 수 있습니다. 이 보고서는 전 세계 결핵 환자 증가, 결핵 연구 자금 지원 증가, 진단 기술 강화 등 결핵균 치료에 대한 수요를 촉진하는 요인에 초점을 맞추었습니다.

시장 성장 촉진요인 :

결핵 치료제에 대한 수요는 여러 가지 요인에 의해 증가하고 있습니다. 전 세계 결핵 환자 증가, 검진 및 진단 수단 강화, 보다 신속하고 효과적인 약물 요법 개발 등이 이러한 성장의 원동력이 되고 있습니다. 약제 내성 결핵 증가는 병용요법이나 장기적인 백신 전략과 같은 새로운 치료 접근법에 대한 연구를 촉진하고 있습니다. 또한 세계 보건 활동과 결핵 프로그램에 대한 자금 지원은 시장 확대에 크게 기여하고 있습니다.

시장 성장 억제요인 :

결핵균 치료 시장은 첨단 결핵균 치료제의 높은 비용, 저소득 국가의 제한된 의료 시설 접근성, 높은 치료 불이동률 등의 문제에 직면해 있습니다. 약제 내성 결핵 관리의 복잡성과 긴 치료 기간도 시장 성장을 저해하는 요인으로 작용하고 있습니다. 복잡한 규제와 국가마다 다른 정부 정책으로 인해 새로운 치료법의 도입이 지연될 수 있습니다.

시장 기회 :

결핵균 치료제 시장에는 큰 혁신의 기회가 존재합니다. 분자생물학과 유전공학의 발전은 약제 내성 결핵균에 대한 보다 효과적인 새로운 치료법을 개발할 수 있는 가능성을 제공합니다. 공공-민간 파트너십과 국제 협력은 연구개발 노력을 가속화하는 한편, 공중보건 캠페인을 강화하여 인지도를 높이고 조기 발견과 치료 프로토콜 준수를 향상시킬 수 있습니다.

이 보고서에서 다룬 주요 질문

• 2024-2032년 결핵균 치료제 시장의 예상 CAGR은?
• 결핵균 치료제 시장의 성장을 가속하는 주요 요인은 무엇인가?
• 가장 큰 시장 점유율을 차지하는 치료 방식은 무엇인가?
• 세계 결핵균 치료제 시장의 주요 기업은?
• 주요 기업은 어떤 전략을 통해 경쟁에서 살아남기 위해 어떤 전략을 채택하고 있는가?

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위/분류
• 시장의 정의/범위/제한
• 포함과 제외

제3장 주요 시장 동향

• 시장에 영향을 미치는 주요 동향
• 제품 혁신/개발 동향

제4장 주요 성공요인

• 지역별 질병 역학
• 규제 시나리오
• PESTLE 분석
• Porter의 산업 분석
• 제조업체별 주요 프로모션 전략
• 공급망 분석

제5장 시장 배경

• 거시경제 요인
• 예측 요인 - 관련성과 영향
• 시장 역학

제6장 COVID-19 위기 분석

• COVID-19와 영향 분석
  • 질환별 매출
  • 치료 유형별 매출
  • 투여 경로별 매출
  • 유통 채널별 매출
  • 국가별 매출
• 2024년 시장 시나리오

제7장 세계의 결핵균 치료 시장의 수요 분석

• 과거 시장 가치 분석(2019-2023년)
• 현재 및 향후 시장 가치 예측(2024-2032년)
  • 전년대비 성장 동향 분석
  • 절대액의 기회 분석

제8장 세계의 결핵균 치료 시장 분석 : 질환별

• 서론/주요 조사 결과
• 과거 시장 규모 분석 : 질환별(2019-2023년)
• 현재 및 향후 시장 규모 분석과 예측 : 질환별(2024-2032년)
  • 잠복결핵
  • 활동성 결핵
• 질환별 시장의 매력 분석

제9장 세계의 결핵균 치료 시장 분석 : 치료 유형별

• 서론/주요 조사 결과
• 과거 시장 규모 분석 : 치료 유형별(2019-2023년)
• 현재 및 향후 시장 규모 분석과 예측 : 치료 유형별(2024-2032년)
  • 제1 선택약
  • 제2 선택약
• 치료 유형별 시장의 매력 분석

제10장 세계의 결핵균 치료 시장 분석 : 투여 경로별

• 서론/주요 조사 결과
• 과거 시장 규모 분석 : 투여 경로별(2019-2023년)
• 현재 및 향후 시장 규모 분석과 예측 : 투여 경로별(2024-2032년)
  • 경구
  • 정맥내
  • 근육내
• 투여 경로별 시장의 매력 분석

제11장 세계의 결핵균 치료 시장 분석 : 유통 채널별

• 서론/주요 조사 결과
• 과거 시장 규모 분석 : 유통 채널별(2019-2023년)
• 현재 및 향후 시장 규모 분석과 예측 : 유통 채널별(2024-2032년)
  • 병원 약국
  • 온라인 약국
  • 소매 약국
  • 법인 및 개인용 판매
• 유통 채널별 시장의 매력 분석

제12장 세계의 결핵균 치료 시장 분석 : 지역별

• 서론
• 과거 시장 규모 분석 : 지역별(2019-2023년)
• 현재 및 향후 시장 규모 분석과 예측 : 지역별(2024-2032년)
  • 북미
  • 라틴아메리카
  • 유럽
  • 동아시아
  • 남아시아
  • 오세아니아
  • 중동 및 아프리카
• 지역별 시장의 매력 분석

제13장 북미의 결핵균 치료 시장 분석

제14장 라틴아메리카의 결핵균 치료 시장 분석

제15장 유럽의 결핵균 치료 시장 분석

제16장 남아시아의 결핵균 치료 시장 분석

제17장 동아시아의 결핵균 치료 시장 분석

제18장 오세아니아의 결핵균 치료 시장 분석

제19장 중동 및 아프리카의 결핵균 치료 시장 분석

제20장 시장 구조 분석

• 기업 계층별 시장 분석
• 주요 기업의 시장 점유율 분석
• 시장 입지 분석

제21장 경쟁 분석

• 경쟁 대시보드
• 경쟁 벤치마킹
• 경쟁의 상세
  • AstraZeneca
  • Johnson &Johnson Private Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Lupin
  • Allergan
  • Merck &Co., Inc.
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Cipla Inc.
  • Endo International plc
  • Otsuka Pharmaceutical Co., Ltd.
  • STI Pharma, LLC

제22장 전제와 두자어

제23장 조사 방법

KSA

영문 목차

영문목차

The Mycobacterium Tuberculosis Treatment Market report by Persistence Market Research provides an in-depth analysis of the market trends, growth drivers, challenges, and prospective innovations spanning from 2024 to 2032. It offers insights into the current landscape and future projections of the market.

The global market for Mycobacterium tuberculosis treatment is expected to achieve a compound annual growth rate (CAGR) of 1.2% from USD 2.13 billion in 2024 to USD 2.40 billion by 2032.

Key Insights:

• Estimated Market Size (2024): USD 2.13 Billion
• Projected Market Size (2032): USD 2.40 Billion
• Global Market Growth Rate (CAGR 2024 to 2032): 1.2%

Mycobacterium Tuberculosis Treatment Market - Report Scope:

Mycobacterium tuberculosis is the bacterium that causes tuberculosis (TB), primarily affecting the lungs but can invade other organs. This report focuses on the drivers promoting the demand for TB treatment, including the global rise in TB cases, increased funding for TB research, and enhancements in diagnostic technologies.

Market Growth Drivers:

The demand for TB treatment is escalating due to several factors. The increase in TB cases globally, enhanced screening and diagnostic measures, and the development of faster-acting and more effective drug regimens drive this growth. The rise of drug-resistant TB forms has spurred research into novel treatment approaches, including combination therapies and longer-term vaccine strategies. Additionally, global health initiatives and funding for TB programs significantly propel market expansion.

Market Restraints:

The Mycobacterium Tuberculosis Treatment Market faces challenges such as the high cost of advanced TB drugs, limited access to medical facilities in low-income countries, and significant rates of treatment non-compliance. The complexity of managing drug-resistant TB and the long duration of treatment also hinder market growth. Regulatory complexities and varying government policies across countries can delay the introduction of new treatments.

Market Opportunities:

Significant opportunities exist for innovation within the TB treatment market. Advances in molecular biology and genetic engineering offer potential for developing new treatments that are more effective against drug-resistant strains of TB. Public-private partnerships and international collaborations can accelerate research and development efforts, while increasing public health campaigns can raise awareness and improve early detection and compliance with treatment protocols.

Key Questions Addressed in the Report:

• What is the Expected CAGR of the Mycobacterium Tuberculosis Treatment Market from 2024 to 2032?
• What are the Key Factors Driving the Growth of the Mycobacterium Tuberculosis Treatment Market?
• Which Treatment Modality Holds the Largest Market Share?
• Who are the Key Players in the Global Mycobacterium Tuberculosis Treatment Market?
• What Strategies are Adopted by Leading Companies to Remain Competitive?

Competitive Landscape and Business Strategies:

Key players in the market include Johnson & Johnson, Sanofi, Bayer AG, and GlaxoSmithKline plc. These companies focus on innovations in TB treatment, market penetration in untapped regions, and forming strategic partnerships to stay competitive. For instance, Johnson & Johnson offers Sirturo for multi-drug resistant TB, and Sanofi has been involved in developing booster combinations to enhance treatment efficacy.

Key Companies Profiled:

• AstraZeneca
• Johnson & Johnson Private Limited
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• Lupin
• Allergan
• Merck & Co., Inc.
• Pfizer Inc.
• GlaxoSmithKline plc
• Hikma Pharmaceuticals PLC
• Cipla Inc.
• Endo International plc
• Otsuka Pharmaceutical Co., Ltd.
• STI Pharma, LLC

Mycobacterium Tuberculosis Treatment Market Segmentation:

By Disease Type:

• Latent TB
• Active TB

By Treatment Type:

• First-Line of Drugs
• Second-Line of Drugs

By Route of Administration:

• Oral
• Intravenous
• Intramuscular

By Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Institutional and Retail Sales

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply-Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions & Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation / Development Trends

4. Key Success Factors

• 4.1. Disease Epidemiology, By Region
• 4.2. Regulatory Scenario
• 4.3. PESTLE Analysis
• 4.4. Porter's Analysis
• 4.5. Key Promotional Strategies, by Manufacturers
• 4.6. Supply Chain Analysis

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Expenditure
  • 5.1.3. Global Infectious Disease Treatment Market
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Growing Burden of Tuberculosis Disease
  • 5.2.2. Increasing Research and Development Activities
  • 5.2.3. Adoption of Different Treatments for Infectious Disease
  • 5.2.4. Rising Government Support
  • 5.2.5. Increasing FDA Approvals of New Drugs
  • 5.2.6. Strategic Mergers and Acquisitions Among Local Manufacturers
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

• 6.1. COVID-19 and Impact Analysis
  • 6.1.1. Revenue By Disease Type
  • 6.1.2. Revenue By Treatment Type
  • 6.1.3. Revenue By Route of Administration
  • 6.1.4. Revenue By Distribution Channel
  • 6.1.5. Revenue By Country
• 6.2. 2024 Market Scenario

7. Global Mycobacterium Tuberculosis Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032

• 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Disease Type

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Mn) Analysis By Disease Type, 2019-2023
• 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Type, 2024-2032
  • 8.3.1. Latent TB
  • 8.3.2. Active TB
• 8.4. Market Attractiveness Analysis By Disease Type

9. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Treatment Type

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2019-2023
• 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Treatment Type, 2024-2032
  • 9.3.1. First-Line of Drugs
  • 9.3.2. Second-Line of Drugs
• 9.4. Market Attractiveness Analysis By Treatment Type

10. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Route of Administration

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2019-2023
• 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2024-2032
  • 10.3.1. Oral
  • 10.3.2. Intravenous
  • 10.3.3. Intramuscular
• 10.4. Market Attractiveness Analysis By Route of Administration

11. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Distribution Channel

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
• 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2032
  • 11.3.1. Hospital Pharmacies
  • 11.3.2. Online Pharmacies
  • 11.3.3. Retail Pharmacies
  • 11.3.4. Institutional and Retail Sales
• 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, by Region

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
• 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2032
  • 12.3.1. North America
  • 12.3.2. Latin America
  • 12.3.3. Europe
  • 12.3.4. East Asia
  • 12.3.5. South Asia
  • 12.3.6. Oceania
  • 12.3.7. Middle East and Africa (MEA)
• 12.4. Market Attractiveness Analysis By Region

13. North America Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
  • 13.3.1. By Country
    • 13.3.1.1. U.S.
    • 13.3.1.2. Canada
  • 13.3.2. By Disease Type
  • 13.3.3. By Treatment Type
  • 13.3.4. By Route of Administration
  • 13.3.5. By Distribution Channel
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Disease Type
  • 13.4.3. By Treatment Type
  • 13.4.4. By Route of Administration
  • 13.4.5. By Distribution Channel
• 13.5. Market Trends
• 13.6. Key Market Participants - Intensity Mapping
• 13.7. Drivers and Restraints - Impact Analysis
• 13.8. Country Level Analysis & Forecast
  • 13.8.1. U.S. Mycobacterium Tuberculosis Treatment Market Analysis
    • 13.8.1.1. Introduction
    • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.1.2.1. By Disease Type
      • 13.8.1.2.2. By Treatment Type
      • 13.8.1.2.3. By Route of Administration
      • 13.8.1.2.4. By Distribution Channel
  • 13.8.2. Canada Mycobacterium Tuberculosis Treatment Market Analysis
    • 13.8.2.1. Introduction
    • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.2.2.1. By Disease Type
      • 13.8.2.2.2. By Treatment Type
      • 13.8.2.2.3. By Route of Administration
      • 13.8.2.2.4. By Distribution Channel

14. Latin America Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
  • 14.3.1. By Country
    • 14.3.1.1. Brazil
    • 14.3.1.2. Mexico
    • 14.3.1.3. Rest of Latin America
  • 14.3.2. By Disease Type
  • 14.3.3. By Treatment Type
  • 14.3.4. By Route of Administration
  • 14.3.5. By Distribution Channel
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Disease Type
  • 14.4.3. By Treatment Type
  • 14.4.4. By Route of Administration
  • 14.4.5. By Distribution Channel
• 14.5. Market Trends
• 14.6. Key Market Participants - Intensity Mapping
• 14.7. Drivers and Restraints - Impact Analysis
• 14.8. Country Level Analysis & Forecast
  • 14.8.1. Brazil Mycobacterium Tuberculosis Treatment Market Analysis
    • 14.8.1.1. Introduction
    • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.1.2.1. By Disease Type
      • 14.8.1.2.2. By Treatment Type
      • 14.8.1.2.3. By Route of Administration
      • 14.8.1.2.4. By Distribution Channel
  • 14.8.2. Argentina Mycobacterium Tuberculosis Treatment Market Analysis
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.2.2.1. By Disease Type
      • 14.8.2.2.2. By Treatment Type
      • 14.8.2.2.3. By Route of Administration
      • 14.8.2.2.4. Distribution Channel
  • 14.8.3. Mexico Mycobacterium Tuberculosis Treatment Market Analysis
    • 14.8.3.1. Introduction
    • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.3.2.1. By Disease Type
      • 14.8.3.2.2. By Treatment Type
      • 14.8.3.2.3. By Route of Administration
      • 14.8.3.2.4. By Distribution Channel

15. Europe Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
  • 15.3.1. By Country
    • 15.3.1.1. Germany
    • 15.3.1.2. Italy
    • 15.3.1.3. France
    • 15.3.1.4. U.K.
    • 15.3.1.5. Spain
    • 15.3.1.6. BENELUX
    • 15.3.1.7. Nordic Countries
    • 15.3.1.8. Russia
    • 15.3.1.9. Rest of Europe
  • 15.3.2. By Disease Type
  • 15.3.3. By Treatment Type
  • 15.3.4. By Route of Administration
  • 15.3.5. By Distribution Channel
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Disease Type
  • 15.4.3. By Treatment Type
  • 15.4.4. By Route of Administration
  • 15.4.5. By Distribution Channel
• 15.5. Market Trends
• 15.6. Key Market Participants - Intensity Mapping
• 15.7. Drivers and Restraints - Impact Analysis
• 15.8. Country Level Analysis & Forecast
  • 15.8.1. Germany Mycobacterium Tuberculosis Treatment Market Analysis
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.1.2.1. By Disease Type
      • 15.8.1.2.2. By Treatment Type
      • 15.8.1.2.3. By Route of Administration
      • 15.8.1.2.4. By Distribution Channel
  • 15.8.2. France Mycobacterium Tuberculosis Treatment Market Analysis
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.2.2.1. By Disease Type
      • 15.8.2.2.2. By Treatment Type
      • 15.8.2.2.3. By Route of Administration
      • 15.8.2.2.4. By Distribution Channel
  • 15.8.3. Italy Mycobacterium Tuberculosis Treatment Market Analysis
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.3.2.1. By Disease Type
      • 15.8.3.2.2. By Treatment Type
      • 15.8.3.2.3. By Route of Administration
      • 15.8.3.2.4. By Distribution Channel
  • 15.8.4. Spain Mycobacterium Tuberculosis Treatment Market Analysis
    • 15.8.4.1. Introduction
    • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.4.2.1. By Disease Type
      • 15.8.4.2.2. By Treatment Type
      • 15.8.4.2.3. By Route of Administration
      • 15.8.4.2.4. By Distribution Channel
  • 15.8.5. U.K. Mycobacterium Tuberculosis Treatment Market Analysis
    • 15.8.5.1. Introduction
    • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.5.2.1. By Disease Type
      • 15.8.5.2.2. By Treatment Type
      • 15.8.5.2.3. By Route of Administration
      • 15.8.5.2.4. By Distribution Channel
  • 15.8.6. Benelux Union Mycobacterium Tuberculosis Treatment Market Analysis
    • 15.8.6.1. Introduction
    • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.6.2.1. By Disease Type
      • 15.8.6.2.2. By Treatment Type
      • 15.8.6.2.3. By Route of Administration
      • 15.8.6.2.4. By Distribution Channel
  • 15.8.7. Nordic Countries Mycobacterium Tuberculosis Treatment Market Analysis
    • 15.8.7.1. Introduction
    • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.7.2.1. By Disease Type
      • 15.8.7.2.2. By Treatment Type
      • 15.8.7.2.3. By Route of Administration
      • 15.8.7.2.4. By Distribution Channel
  • 15.8.8. Russia Mycobacterium Tuberculosis Treatment Market Analysis
    • 15.8.8.1. Introduction
    • 15.8.8.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.8.2.1. By Disease Type
      • 15.8.8.2.2. By Treatment Type
      • 15.8.8.2.3. By Route of Administration
      • 15.8.8.2.4. By Distribution Channel

16. South Asia Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
  • 16.3.1. By Country
    • 16.3.1.1. India
    • 16.3.1.2. Thailand
    • 16.3.1.3. Indonesia
    • 16.3.1.4. Malaysia
    • 16.3.1.5. Rest of South Asia
  • 16.3.2. By Disease Type
  • 16.3.3. By Treatment Type
  • 16.3.4. By Route of Administration
  • 16.3.5. By Distribution Channel
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Disease Type
  • 16.4.3. By Treatment Type
  • 16.4.4. By Route of Administration
  • 16.4.5. By Distribution Channel
• 16.5. Market Trends
• 16.6. Key Market Participants - Intensity Mapping
• 16.7. Drivers and Restraints - Impact Analysis
• 16.8. Country Level Analysis & Forecast
  • 16.8.1. India Mycobacterium Tuberculosis Treatment Market Analysis
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.1.2.1. By Disease Type
      • 16.8.1.2.2. By Treatment Type
      • 16.8.1.2.3. By Route of Administration
      • 16.8.1.2.4. By Distribution Channel
  • 16.8.2. Indonesia Mycobacterium Tuberculosis Treatment Market Analysis
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.2.2.1. By Disease Type
      • 16.8.2.2.2. By Treatment Type
      • 16.8.2.2.3. By Route of Administration
      • 16.8.2.2.4. By Distribution Channel
  • 16.8.3. Malaysia Mycobacterium Tuberculosis Treatment Market Analysis
    • 16.8.3.1. Introduction
    • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.3.2.1. By Disease Type
      • 16.8.3.2.2. By Treatment Type
      • 16.8.3.2.3. By Route of Administration
      • 16.8.3.2.4. By Distribution Channel
      • 16.8.3.2.5. By Distribution Channel
  • 16.8.4. Thailand Mycobacterium Tuberculosis Treatment Market Analysis
    • 16.8.4.1. Introduction
    • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.4.2.1. By Disease Type
      • 16.8.4.2.2. By Treatment Type
      • 16.8.4.2.3. By Route of Administration
      • 16.8.4.2.4. By Distribution Channel

17. East Asia Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
  • 17.3.1. By Country
    • 17.3.1.1. China
    • 17.3.1.2. Japan
    • 17.3.1.3. South Korea
  • 17.3.2. By Disease Type
  • 17.3.3. By Treatment Type
  • 17.3.4. By Route of Administration
  • 17.3.5. By Distribution Channel
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Disease Type
  • 17.4.3. By Treatment Type
  • 17.4.4. By Route of Administration
  • 17.4.5. By Distribution Channel
• 17.5. Market Trends
• 17.6. Key Market Participants - Intensity Mapping
• 17.7. Drivers and Restraints - Impact Analysis
• 17.8. Country Level Analysis & Forecast
  • 17.8.1. China Mycobacterium Tuberculosis Treatment Market Analysis
    • 17.8.1.1. Introduction
    • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.1.2.1. By Disease Type
      • 17.8.1.2.2. By Treatment Type
      • 17.8.1.2.3. By Route of Administration
      • 17.8.1.2.4. By Distribution Channel
  • 17.8.2. Japan Mycobacterium Tuberculosis Treatment Market Analysis
    • 17.8.2.1. Introduction
    • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.2.2.1. By Disease Type
      • 17.8.2.2.2. By Treatment Type
      • 17.8.2.2.3. By Route of Administration
      • 17.8.2.2.4. By Distribution Channel
  • 17.8.3. South Korea Mycobacterium Tuberculosis Treatment Market Analysis
    • 17.8.3.1. Introduction
    • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.3.2.1. By Disease Type
      • 17.8.3.2.2. By Treatment Type
      • 17.8.3.2.3. By Route of Administration
      • 17.8.3.2.4. By Distribution Channel

18. Oceania Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 18.1. Introduction
• 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
  • 18.3.1. By Country
    • 18.3.1.1. Australia
    • 18.3.1.2. New Zealand
  • 18.3.2. By Disease Type
  • 18.3.3. By Treatment Type
  • 18.3.4. By Route of Administration
  • 18.3.5. By Distribution Channel
• 18.4. Market Attractiveness Analysis
  • 18.4.1. By Country
  • 18.4.2. By Disease Type
  • 18.4.3. By Treatment Type
  • 18.4.4. By Route of Administration
  • 18.4.5. By Distribution Channel
• 18.5. Market Trends
• 18.6. Key Market Participants - Intensity Mapping
• 18.7. Drivers and Restraints - Impact Analysis
• 18.8. Country Level Analysis & Forecast
  • 18.8.1. Australia Mycobacterium Tuberculosis Treatment Market Analysis
    • 18.8.1.1. Introduction
    • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.1.2.1. By Disease Type
      • 18.8.1.2.2. By Treatment Type
      • 18.8.1.2.3. By Route of Administration
      • 18.8.1.2.4. By Distribution Channel
  • 18.8.2. New Zealand Mycobacterium Tuberculosis Treatment Market Analysis
    • 18.8.2.1. Introduction
    • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.2.2.1. By Disease Type
      • 18.8.2.2.2. By Treatment Type
      • 18.8.2.2.3. By Route of Administration
      • 18.8.2.2.4. By Distribution Channel

19. Middle East and Africa (MEA) Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 19.1. Introduction
• 19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
  • 19.3.1. By Country
    • 19.3.1.1. GCC Countries
    • 19.3.1.2. Turkey
    • 19.3.1.3. North Africa
    • 19.3.1.4. South Africa
    • 19.3.1.5. Rest of Middle East and Africa
  • 19.3.2. By Disease Type
  • 19.3.3. By Treatment Type
  • 19.3.4. By Route of Administration
  • 19.3.5. By Distribution Channel
• 19.4. Market Attractiveness Analysis
  • 19.4.1. By Country
  • 19.4.2. By Disease Type
  • 19.4.3. By Treatment Type
  • 19.4.4. By Route of Administration
  • 19.4.5. By Distribution Channel
• 19.5. Market Trends
• 19.6. Key Market Participants - Intensity Mapping
• 19.7. Drivers and Restraints - Impact Analysis
• 19.8. Country Level Analysis & Forecast
  • 19.8.1. GCC Countries Mycobacterium Tuberculosis Treatment Market Analysis
    • 19.8.1.1. Introduction
    • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.1.2.1. By Disease Type
      • 19.8.1.2.2. By Treatment Type
      • 19.8.1.2.3. By Route of Administration
      • 19.8.1.2.4. By Distribution Channel
  • 19.8.2. Turkey Mycobacterium Tuberculosis Treatment Market Analysis
    • 19.8.2.1. Introduction
    • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.2.2.1. By Disease Type
      • 19.8.2.2.2. By Treatment Type
      • 19.8.2.2.3. By Route of Administration
      • 19.8.2.2.4. By Distribution Channel
  • 19.8.3. North Africa Mycobacterium Tuberculosis Treatment Market Analysis
    • 19.8.3.1. Introduction
    • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.3.2.1. By Disease Type
      • 19.8.3.2.2. By Treatment Type
      • 19.8.3.2.3. By Route of Administration
      • 19.8.3.2.4. By Distribution Channel
  • 19.8.4. South Africa Mycobacterium Tuberculosis Treatment Market Analysis
    • 19.8.4.1. Introduction
    • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.4.2.1. By Disease Type
      • 19.8.4.2.2. By Treatment Type
      • 19.8.4.2.3. By Route of Administration
      • 19.8.4.2.4. By Distribution Channel

20. Market Structure Analysis

• 20.1. Market Analysis by Tier of Companies
• 20.2. Market Share Analysis of Top Players
• 20.3. Market Presence Analysis
  • 20.3.1. Regional Footprint Analysis
  • 20.3.2. Channel Footprint Analysis

21. Competition Analysis

• 21.1. Competition Dashboard
• 21.2. Competition Benchmarking
• 21.3. Competition Deep Dive
  • 21.3.1. AstraZeneca
    • 21.3.1.1. Overview
    • 21.3.1.2. Product Portfolio
    • 21.3.1.3. Key Financials
    • 21.3.1.4. SWOT Analysis
    • 21.3.1.5. Sales Footprint
    • 21.3.1.6. Strategy Overview
    • 21.3.1.7. Key Developments
      • 21.3.1.7.1. Marketing Strategies
      • 21.3.1.7.2. Channel Strategies
  • 21.3.2. Johnson & Johnson Private Limited
    • 21.3.2.1. Overview
    • 21.3.2.2. Product Portfolio
    • 21.3.2.3. Key Financials
    • 21.3.2.4. SWOT Analysis
    • 21.3.2.5. Sales Footprint
    • 21.3.2.6. Strategy Overview
    • 21.3.2.7. Key Developments
      • 21.3.2.7.1. Marketing Strategies
      • 21.3.2.7.2. Channel Strategies
  • 21.3.3. Eli Lilly and Company
    • 21.3.3.1. Overview
    • 21.3.3.2. Product Portfolio
    • 21.3.3.3. Key Financials
    • 21.3.3.4. SWOT Analysis
    • 21.3.3.5. Sales Footprint
    • 21.3.3.6. Strategy Overview
    • 21.3.3.7. Key Developments
      • 21.3.3.7.1. Marketing Strategies
      • 21.3.3.7.2. Channel Strategies
  • 21.3.4. F. Hoffmann-La Roche Ltd.
    • 21.3.4.1. Overview
    • 21.3.4.2. Product Portfolio
    • 21.3.4.3. Key Financials
    • 21.3.4.4. SWOT Analysis
    • 21.3.4.5. Sales Footprint
    • 21.3.4.6. Strategy Overview
    • 21.3.4.7. Key Developments
      • 21.3.4.7.1. Marketing Strategies
      • 21.3.4.7.2. Channel Strategies
  • 21.3.5. Mylan N.V.
    • 21.3.5.1. Overview
    • 21.3.5.2. Product Portfolio
    • 21.3.5.3. Key Financials
    • 21.3.5.4. SWOT Analysis
    • 21.3.5.5. Sales Footprint
    • 21.3.5.6. Strategy Overview
    • 21.3.5.7. Key Developments
      • 21.3.5.7.1. Marketing Strategies
      • 21.3.5.7.2. Channel Strategies
  • 21.3.6. Teva Pharmaceutical Industries Ltd.
    • 21.3.6.1. Overview
    • 21.3.6.2. Product Portfolio
    • 21.3.6.3. Key Financials
    • 21.3.6.4. SWOT Analysis
    • 21.3.6.5. Sales Footprint
    • 21.3.6.6. Strategy Overview
    • 21.3.6.7. Key Developments
      • 21.3.6.7.1. Marketing Strategies
      • 21.3.6.7.2. Channel Strategies
  • 21.3.7. Sanofi
    • 21.3.7.1. Overview
    • 21.3.7.2. Product Portfolio
    • 21.3.7.3. Key Financials
    • 21.3.7.4. SWOT Analysis
    • 21.3.7.5. Sales Footprint
    • 21.3.7.6. Strategy Overview
    • 21.3.7.7. Key Developments
      • 21.3.7.7.1. Marketing Strategies
      • 21.3.7.7.2. Channel Strategies
  • 21.3.8. Novartis AG
    • 21.3.8.1. Overview
    • 21.3.8.2. Product Portfolio
    • 21.3.8.3. Key Financials
    • 21.3.8.4. SWOT Analysis
    • 21.3.8.5. Sales Footprint
    • 21.3.8.6. Strategy Overview
    • 21.3.8.7. Key Developments
      • 21.3.8.7.1. Marketing Strategies
      • 21.3.8.7.2. Channel Strategies
  • 21.3.9. Sun Pharmaceutical Industries Ltd.
    • 21.3.9.1. Overview
    • 21.3.9.2. Product Portfolio
    • 21.3.9.3. Key Financials
    • 21.3.9.4. SWOT Analysis
    • 21.3.9.5. Sales Footprint
    • 21.3.9.6. Strategy Overview
    • 21.3.9.7. Key Developments
      • 21.3.9.7.1. Marketing Strategies
      • 21.3.9.7.2. Channel Strategies
  • 21.3.10. Aurobindo Pharma
    • 21.3.10.1. Overview
    • 21.3.10.2. Product Portfolio
    • 21.3.10.3. Key Financials
    • 21.3.10.4. SWOT Analysis
    • 21.3.10.5. Sales Footprint
    • 21.3.10.6. Strategy Overview
    • 21.3.10.7. Key Developments
      • 21.3.10.7.1. Marketing Strategies
      • 21.3.10.7.2. Channel Strategies
  • 21.3.11. Lupin
    • 21.3.11.1. Overview
    • 21.3.11.2. Product Portfolio
    • 21.3.11.3. Key Financials
    • 21.3.11.4. SWOT Analysis
    • 21.3.11.5. Sales Footprint
    • 21.3.11.6. Strategy Overview
    • 21.3.11.7. Key Developments
      • 21.3.11.7.1. Marketing Strategies
      • 21.3.11.7.2. Channel Strategies
  • 21.3.12. Allergan
    • 21.3.12.1. Overview
    • 21.3.12.2. Product Portfolio
    • 21.3.12.3. Key Financials
    • 21.3.12.4. SWOT Analysis
    • 21.3.12.5. Sales Footprint
    • 21.3.12.6. Strategy Overview
    • 21.3.12.7. Key Developments
      • 21.3.12.7.1. Marketing Strategies
      • 21.3.12.7.2. Channel Strategies
  • 21.3.13. Merck & Co., Inc.
    • 21.3.13.1. Overview
    • 21.3.13.2. Product Portfolio
    • 21.3.13.3. Key Financials
    • 21.3.13.4. SWOT Analysis
    • 21.3.13.5. Sales Footprint
    • 21.3.13.6. Strategy Overview
    • 21.3.13.7. Key Developments
      • 21.3.13.7.1. Marketing Strategies
      • 21.3.13.7.2. Channel Strategies
  • 21.3.14. Pfizer Inc.
    • 21.3.14.1. Overview
    • 21.3.14.2. Product Portfolio
    • 21.3.14.3. Key Financials
    • 21.3.14.4. SWOT Analysis
    • 21.3.14.5. Sales Footprint
    • 21.3.14.6. Strategy Overview
    • 21.3.14.7. Key Developments
      • 21.3.14.7.1. Marketing Strategies
      • 21.3.14.7.2. Channel Strategies
  • 21.3.15. GlaxoSmithKline plc
    • 21.3.15.1. Overview
    • 21.3.15.2. Product Portfolio
    • 21.3.15.3. Key Financials
    • 21.3.15.4. SWOT Analysis
    • 21.3.15.5. Sales Footprint
    • 21.3.15.6. Strategy Overview
    • 21.3.15.7. Key Developments
      • 21.3.15.7.1. Marketing Strategies
      • 21.3.15.7.2. Channel Strategies
  • 21.3.16. Hikma Pharmaceuticals PLC
    • 21.3.16.1. Overview
    • 21.3.16.2. Product Portfolio
    • 21.3.16.3. Key Financials
    • 21.3.16.4. SWOT Analysis
    • 21.3.16.5. Sales Footprint
    • 21.3.16.6. Strategy Overview
    • 21.3.16.7. Key Developments
      • 21.3.16.7.1. Marketing Strategies
      • 21.3.16.7.2. Channel Strategies
  • 21.3.17. Cipla Inc.
    • 21.3.17.1. Overview
    • 21.3.17.2. Product Portfolio
    • 21.3.17.3. Key Financials
    • 21.3.17.4. SWOT Analysis
    • 21.3.17.5. Sales Footprint
    • 21.3.17.6. Strategy Overview
    • 21.3.17.7. Key Developments
      • 21.3.17.7.1. Marketing Strategies
      • 21.3.17.7.2. Channel Strategies
  • 21.3.18. Endo International plc
    • 21.3.18.1. Overview
    • 21.3.18.2. Product Portfolio
    • 21.3.18.3. Key Financials
    • 21.3.18.4. SWOT Analysis
    • 21.3.18.5. Sales Footprint
    • 21.3.18.6. Strategy Overview
    • 21.3.18.7. Key Developments
      • 21.3.18.7.1. Marketing Strategies
      • 21.3.18.7.2. Channel Strategies
  • 21.3.19. Otsuka Pharmaceutical Co., Ltd.
    • 21.3.19.1. Overview
    • 21.3.19.2. Product Portfolio
    • 21.3.19.3. Key Financials
    • 21.3.19.4. SWOT Analysis
    • 21.3.19.5. Sales Footprint
    • 21.3.19.6. Strategy Overview
    • 21.3.19.7. Key Developments
      • 21.3.19.7.1. Marketing Strategies
      • 21.3.19.7.2. Channel Strategies
  • 21.3.20. STI Pharma, LLC
    • 21.3.20.1. Overview
    • 21.3.20.2. Product Portfolio
    • 21.3.20.3. Key Financials
    • 21.3.20.4. SWOT Analysis
    • 21.3.20.5. Sales Footprint
    • 21.3.20.6. Strategy Overview
    • 21.3.20.7. Key Developments
      • 21.3.20.7.1. Marketing Strategies
      • 21.3.20.7.2. Channel Strategies

22. Assumptions and Acronyms Used

23. Research Methodology

관련자료